-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] After years of market verification, the investment value of the pharmaceutical sector is considered to be the "blue ocean" of investment
.
Industry insiders suggest that investors should pay attention to pharmaceutical companies in three sub-sectors: companies with strong innovation capabilities; companies that conform to the direction of national policy development; and the traditional Chinese medicine industry
.
From the perspective of individual stocks, according to statistics, individual stocks such as Anxu Bio, Rejing Bio, Asia Pacific Pharmaceutical, and Aotai Bio all rose by more than 50% within a month
.
According to data from Anxu Biology, Anxu Biology rose by 79.
61 within a month, and achieved a daily limit of 20cm for four consecutive trading days
.
According to the data, Anxu Bio is a biopharmaceutical enterprise integrating R&D, production and sales of in vitro diagnostic reagents, POCT instruments and biological raw materials.
At present, its main business is drug and infectious disease detection, supplemented by other tests such as pregnancy and tumor.
.
The company is deeply engaged in overseas markets, and overseas revenue accounts for more than 90%.
It is estimated that in 2021-23, Anxu Bio will achieve a net profit of 7.
26/2.
988 billion yuan/1.
655 billion yuan, a year-on-year increase of 11.
9%/311.
5%/-44.
6%
.
According to the industry, it continues to be optimistic about the POCT testing track with a broad market.
Anxu Bio is a core POCT reagent provider with high raw material self-supply capability and rich categories in the track.
The company can also use a large amount of profitable cash for product research and development, channel expansion and Increased production capacity and broad prospects
.
According to the data of Hot View Bio, Hot View Bio increased by 59.
28% within the month
.
According to the data, Rejing Bio is a biological high-tech enterprise engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments.
It is mainly engaged in two types of in vitro diagnostic reagents and instruments.
Clinical fields such as infection and public safety and other fields such as biosecurity, food safety, disease control and emergency response
.
Recently, Rejing Bio released the 2021 annual performance forecast.
The company expects to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%
.
According to data from the Asia-Pacific Pharmaceutical Industry, the Asia-Pacific Pharmaceutical Industry rose 56.
25% in the month
.
According to the data, Asia Pacific Pharmaceuticals is an enterprise dedicated to the research and development, production and sales of chemical preparations, focusing on the primary medical care market
.
The company's current production of antibiotic drugs mainly include amoxicillin and clavulanate potassium dispersible tablets, azithromycin dispersible tablets, azithromycin for injection, roxithromycin capsules, ceftizoxime sodium for injection, etc.
; the company's digestive system drugs mainly include injection Use pantoprazole sodium, omeprazole sodium for injection, omeprazole enteric-coated capsules, lansoprazole enteric-coated capsules,
etc.
According to the data of Aotai Biology, Aotai Biology increased by 52.
83% within the month
.
According to the data, Aotai Bio focuses on the POCT segment in the in vitro diagnostic industry.
Its main business is the research and development, production and sales of in vitro diagnostic reagents.
Its main products are rapid diagnostic reagents, including drug and drug abuse detection, infectious disease detection, Five series of women's health detection, tumor detection and cardiac marker detection
.
Data show that in the first half of 2021, the operating income of Aotai Bio was about 636 million yuan, a year-on-year increase of 30.
48%; the net profit attributable to shareholders of listed companies was about 326 million yuan, a year-on-year increase of 3.
57%
.
.
Industry insiders suggest that investors should pay attention to pharmaceutical companies in three sub-sectors: companies with strong innovation capabilities; companies that conform to the direction of national policy development; and the traditional Chinese medicine industry
.
From the perspective of individual stocks, according to statistics, individual stocks such as Anxu Bio, Rejing Bio, Asia Pacific Pharmaceutical, and Aotai Bio all rose by more than 50% within a month
.
According to data from Anxu Biology, Anxu Biology rose by 79.
61 within a month, and achieved a daily limit of 20cm for four consecutive trading days
.
According to the data, Anxu Bio is a biopharmaceutical enterprise integrating R&D, production and sales of in vitro diagnostic reagents, POCT instruments and biological raw materials.
At present, its main business is drug and infectious disease detection, supplemented by other tests such as pregnancy and tumor.
.
The company is deeply engaged in overseas markets, and overseas revenue accounts for more than 90%.
It is estimated that in 2021-23, Anxu Bio will achieve a net profit of 7.
26/2.
988 billion yuan/1.
655 billion yuan, a year-on-year increase of 11.
9%/311.
5%/-44.
6%
.
According to the industry, it continues to be optimistic about the POCT testing track with a broad market.
Anxu Bio is a core POCT reagent provider with high raw material self-supply capability and rich categories in the track.
The company can also use a large amount of profitable cash for product research and development, channel expansion and Increased production capacity and broad prospects
.
According to the data of Hot View Bio, Hot View Bio increased by 59.
28% within the month
.
According to the data, Rejing Bio is a biological high-tech enterprise engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments.
It is mainly engaged in two types of in vitro diagnostic reagents and instruments.
Clinical fields such as infection and public safety and other fields such as biosecurity, food safety, disease control and emergency response
.
Recently, Rejing Bio released the 2021 annual performance forecast.
The company expects to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%
.
According to data from the Asia-Pacific Pharmaceutical Industry, the Asia-Pacific Pharmaceutical Industry rose 56.
25% in the month
.
According to the data, Asia Pacific Pharmaceuticals is an enterprise dedicated to the research and development, production and sales of chemical preparations, focusing on the primary medical care market
.
The company's current production of antibiotic drugs mainly include amoxicillin and clavulanate potassium dispersible tablets, azithromycin dispersible tablets, azithromycin for injection, roxithromycin capsules, ceftizoxime sodium for injection, etc.
; the company's digestive system drugs mainly include injection Use pantoprazole sodium, omeprazole sodium for injection, omeprazole enteric-coated capsules, lansoprazole enteric-coated capsules,
etc.
According to the data of Aotai Biology, Aotai Biology increased by 52.
83% within the month
.
According to the data, Aotai Bio focuses on the POCT segment in the in vitro diagnostic industry.
Its main business is the research and development, production and sales of in vitro diagnostic reagents.
Its main products are rapid diagnostic reagents, including drug and drug abuse detection, infectious disease detection, Five series of women's health detection, tumor detection and cardiac marker detection
.
Data show that in the first half of 2021, the operating income of Aotai Bio was about 636 million yuan, a year-on-year increase of 30.
48%; the net profit attributable to shareholders of listed companies was about 326 million yuan, a year-on-year increase of 3.
57%
.
